 |
Astex Pharmaceuticals to Present at ASCO Annual Meeting
May 16, 2012
|
18.5 KB |
|
| |
DUBLIN, Calif., May 16, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster discu...
|
|
Astex Pharmaceuticals Reports 2012 First Quarter Financial Results
Apr 30, 2012
|
37.1 KB |
|
| |
Reports First Quarter Net Income of $4.2 Million
Dacogen Royalty Revenue Increases 21% from Prior Year
Ends First Quarter with $126 Million in Cash & Marketable Securities
DUBLIN, Calif., April 30, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), today reported financial results for the first quarter ende...
|
|
Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012
Apr 24, 2012
|
20.3 KB |
|
| |
DUBLIN, Calif., April 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2012 first quarter financial results on Monday, April 30, 2012. James S.J. Manuso, PhD, chairman and chief ex...
|
|
Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment of HCV at EASL
Apr 13, 2012
|
13.6 KB |
|
| |
DUBLIN, Calif., April 13, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX - News), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it will present data on AT26893, a novel, first-in-class, direct acting a...
|
|
Astex Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
Apr 13, 2012
|
12.0 KB |
|
| |
DUBLIN, Calif., April 13, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX - News), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that ...
|
|
Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 MDS and AML Data Presentation at AACR
Apr 3, 2012
|
21.5 KB |
|
| |
DUBLIN, Calif., April 3, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that interim Phase 1/2 clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good t...
|
|
Astex Pharmaceuticals to Present at AACR Annual Meeting
Mar 29, 2012
|
13.0 KB |
|
| |
DUBLIN, Calif., Mar 29, 2012 (BUSINESS WIRE) --
Astex Pharmaceuticals, Inc.
/quotes/zigman/6481310...
|
|
Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda
Mar 21, 2012
|
14.4 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery and development of novel small molecule
therapeutics, today announced the Agenda for its Annual Analyst and
Investor Day webcast, to take place from 10 am to 12 pm ET on Tuesday,
...
|
|
Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia
Mar 6, 2012
|
66.7 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) today announced that the U.S.
Food and Drug Administration has issued a Complete Response Letter to
partner Eisai for their supplemental New Drug Application (sNDA) for
Dacogen® (decitabine) for Injection for patients with acute mye...
|
|
Astex Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 5, 2012
|
35.9 KB |
|
| |
Reports Annual Net Income of $5.5 Million
Dacogen Royalty Revenue Increases 15% from Prior Year
Ends Year with $128 Million in Cash & Marketable Securities
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), today reported financial
...
|
|
Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012
Feb 28, 2012
|
12.9 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery and development of novel small molecule
therapeutics, today announced that it will release its 2011 fourth
quarter and fiscal year-end results on Monday, March 5, 2012. James S.J.
...
|
|
Astex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012
Feb 16, 2012
|
12.6 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery and development of novel small molecule
therapeutics, today announced its Annual Analyst and Investor Day will
take place from 10 am to 1 pm ET on Tuesday, March 27th in New York.
...
|
|
FDA's Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia
Feb 9, 2012
|
66.9 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) today announced that the U.S.
Food and Drug Administration's (FDA's) Oncologic Drugs Advisory
Committee (ODAC) voted 10 to 3 with one person abstaining that data in
our partner Eisai's supplemental new Drug Application (sNDA) for
...
|
|
Astex Pharmaceuticals Announces Presentations at Upcoming Conferences
Feb 6, 2012
|
13.6 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery and development of novel small molecule
therapeutics, today announced that James S.J. Manuso, PhD, chairman and
chief executive officer, will present at the following conferences:
...
|
|
Astex Announces Early Transfer of Epigenetics Project to GSK
Jan 16, 2012
|
14.9 KB |
|
| |
Astex's Pyramid™ Drug Discovery Collaboration With GSK on Multiple
Targets Across Multiple Therapeutics Areas Continues
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) today announced that the
multi-year collaboration to discover cancer therapeutics based o...
|
|
Astex Pharmaceuticals to Present at Biotech Showcase on January 9th
Jan 3, 2012
|
10.1 KB |
|
| |
DUBLIN, Calif.(BUSINESS WIRE)
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company
dedicated to the discovery and development of novel therapeutics, today
announced that James S.J. Manuso, Ph.D., chairman and chief executive
officer, will present at Biotech Showcase 2012 on Monday, January 9th in
S...
|
|
Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML
Dec 29, 2011
|
17.8 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the
pre-publication notice of the Food and Drug Administration (FDA),
Oncologic Drugs Advisory Committee (ODAC) Meeting to discuss the
supplemental new drug application (sNDA) for Dacogen®
(decitabine) for ...
|
|
Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results
Oct 31, 2011
|
40.5 KB |
|
| |
Completes Acquisition of Astex Therapeutics Limited
Dacogen Royalty Revenue Increases 26% from Prior Year
Ends Quarter with $128 Million in Cash & Marketable Securities
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), formerly Supe...
|
|
Astex Pharmaceuticals to Present a Novel Targeted Approach to the Treatment of HCV at the AASLD Meeting
Oct 31, 2011
|
14.2 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery, development and commercialization of novel
therapeutics, announced that it will present data on its novel,
first-in-class direct acting antiviral agents (DAA) against Hepatitis C
...
|
|
Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO
Sep 27, 2011
|
15.6 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company
dedicated to the discovery and development of novel cancer therapies,
announced that preclinical data demonstrating that AT13387, a novel
non-ansamycin Heat Shock Protein 90 (HSP90) inhibitor, is active in in
...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz